About NT PHARMA-NEW Company

Established in 1995, China Tailing Pharmaceutical Group is a comprehensive pharmaceutical group mainly engaged in investment R&D, production, marketing and promotion of pharmaceuticals and new medical technologies. On 2011/4/20, the Group was listed on the main board of the Hong Kong Stock Exchange (stock code: 01011.HK). The group is headquartered in Hong Kong, China, with an investment and marketing management headquarters in Shanghai, an R&D company in Beijing, and has dozens of R&D, pharmaceutical and sales companies across the country, including Hong Kong, Shanghai, Jiangsu, Beijing, Guangzhou, Changsha, and Hainan. The group focuses on developing its own brand core products, covering various treatment fields such as tumors and hematological diseases, digestive diseases, central nervous system diseases, respiratory diseases, etc. There are 131 product registration numbers approved by the China Food and Drug Administration. Among these, more than 20 products are being produced and sold in pharmaceutical companies under the Group.